演題速報 デイリーランキング
このサイトは医療関係者の方々を対象に作成しています。
必ずご利用規約に同意の上、ご利用ください。記事内容で取り上げた薬剤の効能・効果および用法・用量には、日本国内で承認されている内容と異なるものが、多分に含まれていますのでご注意ください。
6月3日 演題レポート
Abstract #LBA3500
Bevacizumab with or without Erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bevacizumab, in patients with metastatic colorectal cancer: Efficacy and safety results of the International GERCOR DREAM phase III trial
Christophe Tournigand, et al.
Abstract #LBA3501
Results of the X-PECT study: A phase III randomized double-blind placebo-controlled study of Perifosine plus Capecitabine (P-CAP) vs. placebo plus Capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC)
Johanna C. Bendell, et al.
Abstract #3502
Phase III CORRECT trial of Regorafenib in metastatic colorectal cancer (mCRC)
Eric Van Cutsem, et al.
Abstract #CRA3503
Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV + CT: Results of a randomised phase III intergroup study - TML (ML18147)
Dirk Arnold, et al.
Abstract #3504
Phase III randomized trial of Cetuximab + either Brivanib alaninate or placebo in patients with chemotherapy refractory, KRAS wild-type colorectal carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 trial
Lillian L. Siu, et al.
Abstract #3505
Effects of prior Bevacizumab use on outcomes from the VELOUR study: A phase III study of Aflibercept and FOLFIRI in patients with metastatic colorectal cancer after failure of an Oxaliplatin regimen
Carmen Joseph Allegra, et al.
Abstract #3506
FOLFOX4 (12 cycles) versus sequential dose-dense FOLFOX7 (6 cycles) followed by FOLFIRI (6 cycles) in patients with initially resectable metastatic colorectal cancer: A GERCOR Randomized Phase III study (MIROX)
Mohamed Habber, et al.
Abstract #3507
Impact on survival of primary tumor resection in patients with colorectal cancer and unresectable metastasis: Pooled analysis of individual patients’ data from four randomized trials
Matthieu Faron, et al.
Abstract #3508
Peri-operative FOLFOX4 chemotherapy and surgery for resectable liver metastases from colorectal cancer: Long-term survival results of the EORTC intergroup phase III study 40983
Bernard Nordlinger, et al.